Cardiff Oncology (NASDAQ:CRDF - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $0.09 million for the quarter.
Cardiff Oncology Price Performance
Cardiff Oncology stock opened at $2.94 on Thursday. Cardiff Oncology has a fifty-two week low of $2.01 and a fifty-two week high of $5.64. The firm has a fifty day moving average price of $3.52 and a two-hundred day moving average price of $3.46. The firm has a market cap of $195.58 million, a price-to-earnings ratio of -3.13 and a beta of 1.74.
Wall Street Analyst Weigh In
Separately, HC Wainwright increased their target price on Cardiff Oncology from $13.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, February 28th.
Read Our Latest Research Report on Cardiff Oncology
About Cardiff Oncology
(
Get Free Report)
Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cardiff Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiff Oncology wasn't on the list.
While Cardiff Oncology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
